Additionally, a growing number of clinical investigations have proven that EPZ015666 can exhibit antitumor properties by inactivating PRMT5 in acute myeloid leukemia [23], lung cancer [19,22], and retinoblastoma [24,25], and is a novel and potential therapeutic target independent of the SAM binding site. Here, PRMT5 is linked to lung carcinoma.